NQF endorses pulmonary and infectious disease measures

Luke Gale | | Health Exec | Economics

The National Quality Forum (NQF) has endorsed 14 infectious disease quality measures and an additional pulmonary quality measure.

The endorsements were made as NQF engages in an quality measure maintenance program to ensure that they are current, best-in-class and synchronistic with with national priorities, according to a Jan. 8 statement.

Visit the NQF website to view more details on the pulmonary and infectious disease quality measures. 

Luke Gale

Related Content

Bill to regulate healthcare private equity lands on desk of Mass. governor
Mayo Clinic sues insurer over $740K in medical bills for patient
The biggest obstacles facing radiology business managers in 2025
Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations

Around the web

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Radiology Business
Policies and regulations shaping radiology in 2025

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year. 

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.